Equities research analysts forecast that Prestige Consumer Healthcare Inc (NYSE:PBH) will announce sales of $236.90 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Prestige Consumer Healthcare’s earnings, with the highest sales estimate coming in at $239.10 million and the lowest estimate coming in at $234.90 million. Prestige Consumer Healthcare posted sales of $255.97 million in the same quarter last year, which would suggest a negative year over year growth rate of 7.5%. The company is expected to announce its next earnings report before the market opens on Thursday, May 9th.
On average, analysts expect that Prestige Consumer Healthcare will report full-year sales of $971.65 million for the current fiscal year, with estimates ranging from $969.70 million to $973.90 million. For the next year, analysts expect that the business will report sales of $956.18 million, with estimates ranging from $950.00 million to $959.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Prestige Consumer Healthcare.
Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, February 7th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.02. The business had revenue of $241.40 million for the quarter, compared to analyst estimates of $241.40 million. Prestige Consumer Healthcare had a return on equity of 11.85% and a net margin of 6.44%. The company’s quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.70 earnings per share.
NYSE:PBH traded up $0.24 on Friday, hitting $29.65. The stock had a trading volume of 3,139 shares, compared to its average volume of 546,381. The firm has a market cap of $1.52 billion, a P/E ratio of 11.48, a PEG ratio of 1.66 and a beta of 0.96. The company has a debt-to-equity ratio of 1.49, a quick ratio of 1.34 and a current ratio of 2.28. Prestige Consumer Healthcare has a 52 week low of $26.25 and a 52 week high of $41.76.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth about $18,328,000. Dimensional Fund Advisors LP boosted its holdings in Prestige Consumer Healthcare by 11.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,049,957 shares of the company’s stock worth $125,062,000 after buying an additional 420,265 shares during the period. LSV Asset Management boosted its holdings in Prestige Consumer Healthcare by 183.1% in the 4th quarter. LSV Asset Management now owns 491,784 shares of the company’s stock worth $15,186,000 after buying an additional 318,043 shares during the period. JPMorgan Chase & Co. boosted its holdings in Prestige Consumer Healthcare by 9.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,030,923 shares of the company’s stock worth $114,842,000 after buying an additional 255,561 shares during the period. Finally, BlackRock Inc. boosted its holdings in Prestige Consumer Healthcare by 4.0% in the 4th quarter. BlackRock Inc. now owns 6,457,359 shares of the company’s stock worth $199,402,000 after buying an additional 248,243 shares during the period.
Prestige Consumer Healthcare Company Profile
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.
Recommended Story: What is Compound Interest?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.